CRIS Current Research Information System

DI FEDERICO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.949
NA - Nord America 1.684
EU - Europa 1.367
AF - Africa 168
SA - Sud America 147
OC - Oceania 3
Totale 6.318
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.654
CN - Cina 913
SG - Singapore 885
IT - Italia 527
VN - Vietnam 476
HK - Hong Kong 274
NL - Olanda 160
DE - Germania 151
KR - Corea 144
IN - India 139
SE - Svezia 113
BR - Brasile 106
FI - Finlandia 78
GB - Regno Unito 75
CI - Costa d'Avorio 61
IE - Irlanda 57
CH - Svizzera 53
FR - Francia 41
RU - Federazione Russa 37
TG - Togo 35
JP - Giappone 31
SC - Seychelles 31
ID - Indonesia 27
NG - Nigeria 26
JO - Giordania 24
AR - Argentina 23
AT - Austria 22
CA - Canada 18
MX - Messico 12
BG - Bulgaria 11
PL - Polonia 10
ZA - Sudafrica 8
BE - Belgio 6
EC - Ecuador 6
ES - Italia 6
TR - Turchia 6
IQ - Iraq 5
LT - Lituania 5
BD - Bangladesh 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
IL - Israele 3
PK - Pakistan 3
PY - Paraguay 3
UA - Ucraina 3
AZ - Azerbaigian 2
BY - Bielorussia 2
GR - Grecia 2
KE - Kenya 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GM - Gambi 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MY - Malesia 1
PE - Perù 1
PH - Filippine 1
TW - Taiwan 1
Totale 6.318
Salva come PNG Salva come JPEG
Città #
Singapore 604
Hefei 337
Ashburn 327
Hong Kong 271
Dallas 166
Seoul 143
Beijing 128
Ho Chi Minh City 127
Santa Clara 125
Chandler 116
Hanoi 111
Bologna 106
Boardman 65
Abidjan 61
Fairfield 61
Dublin 57
Dong Ket 54
Helsinki 49
Los Angeles 48
Bern 43
Milan 42
Seattle 38
Princeton 37
Southend 36
Lomé 35
Hyderabad 33
Munich 33
New York 32
Bengaluru 31
Houston 29
Turin 26
Buffalo 25
Amman 24
Redondo Beach 24
Rome 24
Woodbridge 24
Tokyo 23
Cinquefrondi 22
Abeokuta 20
Falkenstein 19
Wilmington 19
Jakarta 17
Frankfurt am Main 16
Guangzhou 16
Turku 16
Visakhapatnam 16
Haiphong 15
Messina 15
Shanghai 15
Cambridge 13
Modena 13
Tongling 13
Lappeenranta 12
London 12
San Diego 12
Tianjin 12
Sofia 11
São Paulo 11
Biên Hòa 10
Da Nang 10
Ha Long 10
Moncalieri 10
Amsterdam 9
Nuremberg 9
Quận Một 9
Vienna 9
Boydton 8
Florence 8
Hải Dương 8
Ninh Bình 8
Stockholm 8
Xi'an 8
Berlin 7
Bắc Giang 7
Bắc Ninh 7
Orem 7
Quận Bình Thạnh 7
San Francisco 7
Toronto 7
Warsaw 7
Boston 6
Brooklyn 6
Brussels 6
Cesena 6
Elk Grove Village 6
Rancho Palos Verdes 6
Redmond 6
Bremen 5
Can Tho 5
Changsha 5
Chicago 5
Chongqing 5
Denver 5
Des Moines 5
Düsseldorf 5
Indianapolis 5
Jinan 5
Johannesburg 5
Manchester 5
Montreal 5
Totale 4.117
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 237
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 187
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 173
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 172
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 160
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 156
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 152
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 144
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 142
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 137
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 136
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 134
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 132
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 131
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 129
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 128
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 124
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 118
Hacking pancreatic cancer: Present and future of personalized medicine 117
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 116
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 115
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 114
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 112
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 112
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 110
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 108
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 101
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report 101
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma 97
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 96
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 94
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 93
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 91
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 88
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 88
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 86
Nivolumab: an investigational agent for the treatment of biliary tract cancer 85
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 82
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 78
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 76
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 73
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 73
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 69
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 68
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 66
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 64
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 64
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 64
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 63
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 63
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 60
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 57
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 57
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 55
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 53
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 52
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 47
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 47
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 45
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 44
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 42
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 41
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 40
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 39
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 39
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 39
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 39
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 30
Totale 6.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 0 0 0 0 0 30 8 5 11 8 7 70
2021/2022355 15 1 4 17 16 8 4 49 50 25 119 47
2022/2023734 38 77 35 42 102 57 29 51 141 40 50 72
2023/2024359 45 33 19 25 21 65 13 41 13 33 38 13
2024/20252.078 89 145 176 119 216 102 216 93 46 216 211 449
2025/20262.700 673 620 499 441 372 95 0 0 0 0 0 0
Totale 6.474